Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.